A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab as Monotherapy or in Addition to Baseline Therapy in Patients with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)

Protocol No
NEURO-ROCHE-METEOROID
Staff Member
Ahmed Obeidat
Phase
III
Summary

This project is being done to compare the effects, good or bad, of satralizumab with placebo alone or in combination with current treatment (baseline/background therapy) on patients with MOGAD.
Objective
Satralizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (Meteoroid)
Study Sites
Froedtert Hospital
Status
OPEN TO ACCRUAL
Categories
Brain, Spinal Cord, and Nervous System, Multiple Sclerosis
ClinicalTrials.gov
https://www.clinicaltrials.gov/study/NCT05271409